Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Profit After Tax (2016 - 2026)

Insight Molecular Diagnostics' Profit After Tax history spans 6 years, with the latest figure at -$23.0 million for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 31.5% to -$23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$50.2 million, a 17.21% increase, with the full-year FY2025 number at -$50.2 million, up 17.21% from a year prior.
  • Profit After Tax hit -$23.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$10.9 million in the prior quarter.
  • Over the last five years, Profit After Tax for IMDX hit a ceiling of $3.0 million in Q1 2023 and a floor of -$45.0 million in Q4 2022.
  • Historically, Profit After Tax has averaged -$13.1 million across 5 years, with a median of -$9.5 million in 2022.
  • The widest YoY moves for Profit After Tax: up 188.87% in 2023, down 510.92% in 2023.
  • Tracing IMDX's Profit After Tax over 5 years: stood at -$35.9 million in 2021, then decreased by 25.34% to -$45.0 million in 2022, then soared by 64.44% to -$16.0 million in 2023, then crashed by 109.55% to -$33.5 million in 2024, then surged by 31.5% to -$23.0 million in 2025.
  • Business Quant data shows Profit After Tax for IMDX at -$23.0 million in Q4 2025, -$10.9 million in Q3 2025, and -$9.7 million in Q2 2025.